These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 730072)

  • 1. Vasoactive intestinal peptide in man: pharmacokinetics, metabolic and circulatory effects.
    Domschke S; Domschke W; Bloom SR; Mitznegg P; Mitchell SJ; Lux G; Strunz U
    Gut; 1978 Nov; 19(11):1049-53. PubMed ID: 730072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radioimmunoassay study of hepatic clearance and disappearance half-time of somatostatin and vasoactive intestinal peptide in dogs.
    Chayvialle JA; Rayford PL; Thompson JC
    Gut; 1981 Sep; 22(9):732-7. PubMed ID: 6117506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. VIP measurement in distinguishing Verner-Morrison syndrome and pseudo Verner-Morrison syndrome.
    Bloom SR; Polak JM
    Clin Endocrinol (Oxf); 1976; 5 Suppl():223S-228S. PubMed ID: 212228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Vasoactive intestinal peptide (VIP) in the Verner-Morrison syndrome (author's transl)].
    Grenier JF; Marescaux J; Michel F; Sava G; Kachelhoffer J
    Nouv Presse Med; 1979 Apr; 8(18):1505-8. PubMed ID: 224378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peptide YY kinetics and effects on blood pressure and circulating pancreatic and gastrointestinal hormones and metabolites in man.
    Adrian TE; Sagor GR; Savage AP; Bacarese-Hamilton AJ; Hall GM; Bloom SR
    J Clin Endocrinol Metab; 1986 Oct; 63(4):803-7. PubMed ID: 3755728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enteric release of vasoactive intestinal peptide after a peptone meal in the dog.
    Wolfe MM; Misbin RI; Gardner DF; McGuigan JE
    Regul Pept; 1983 Jan; 5(2):103-9. PubMed ID: 6828775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Release of oxytocin and vasopressin by intracerebroventricular vasoactive intestinal polypeptide.
    Bardrum B; Ottesen B; Fahrenkrug J; Fuchs AR
    Endocrinology; 1988 Nov; 123(5):2249-54. PubMed ID: 3168920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Release of VIP, secretin and motilin after duodenal acidification in man.
    Bloom SR; Mitchell SJ; Greenberg GR; Christofides N; Domschke W; Domschke S; Mitznegg P; Demling L
    Acta Hepatogastroenterol (Stuttg); 1978 Oct; 25(5):365-8. PubMed ID: 726803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Verner-Morrison syndrome and vasoactive intestinal polypeptide (VIP).
    Fahrenkrug J; Schaffalitzky de Muckadell OB
    Scand J Gastroenterol Suppl; 1979; 53():57-60. PubMed ID: 225790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of vasoactive intestinal polypeptide on renal function in man.
    Calam J; Dimaline R; Peart WS; Singh J; Unwin RJ
    J Physiol; 1983 Dec; 345():469-75. PubMed ID: 6363677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infusion of vasoactive intestinal polypeptide in man: pharmacokinetics and effect on gastric acid secretion.
    Holm-Bentzen M; Christiansen J; Petersen B; Fahrenkrug J; Schultz A; Kirkegaard P
    Scand J Gastroenterol; 1981 Apr; 16(3):429-32. PubMed ID: 16435487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pharmacokinetics of VIP in dog and pig.
    Mitchell SJ; Modlin IM; D'Sa Barros AA; Bloom SR
    Experientia; 1982 Sep; 38(9):1091-3. PubMed ID: 7128757
    [No Abstract]   [Full Text] [Related]  

  • 13. Hepatic inactivation of vasoactive intestinal peptide in man and dog.
    Ebeid AM; Escourrou J; Soeters PB; Murray P; Fischer JE
    Ann Surg; 1978 Jul; 188(1):28-33. PubMed ID: 666373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of VIP infusion in water and ion transport in the human jejunum.
    Krejs GJ; Fordtran JS; Fahrenkrug J; Schaffalitzky de Muckadell OB; Fischer JE; Humphrey CS; O'Dorisio TM; Said SI; Walsh JH; Shulkes AA
    Gastroenterology; 1980 Apr; 78(4):722-7. PubMed ID: 7353759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myoelectric effects of vasoactive intestinal peptide on rabbit small intestine.
    Sninsky CA; Wolfe MM; Martin JL; Howe BA; O'Dorisio TM; McGuigan JE; Mathias JR
    Am J Physiol; 1983 Jan; 244(1):G46-51. PubMed ID: 6849393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal function during vasoactive intestinal peptide (VIP) infusions in normal man and patients with liver disease.
    Calam J; Unwin RJ; Singh J; Dorudi S; Peart WS
    Peptides; 1984; 5(2):441-3. PubMed ID: 6382198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of peptide YY on the human cardiovascular system: reversal of responses to vasoactive intestinal peptide.
    Playford RJ; Benito-Orfila MA; Nihoyannopoulos P; Nandha KA; Cockcroft J; Todd S; Ghatei MA; Domin J; Bloom SR; Calam J
    Am J Physiol; 1992 Oct; 263(4 Pt 1):E740-7. PubMed ID: 1415694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclical release of vasoactive intestinal polypeptide (VIP) from a pancreatic islet cell apudoma.
    Devine BL; Carmichael HA; Russell RI; Joffe SN
    Postgrad Med J; 1978 Aug; 54(634):566-70. PubMed ID: 215990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of the ventilatory, cardiovascular and metabolic effects of salbutamol, aminophylline and vasoactive intestinal peptide in normal subjects.
    Morice AH; Schofield P; Keal EE; Sever PS
    Br J Clin Pharmacol; 1986 Aug; 22(2):149-53. PubMed ID: 3756064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Release of vasoactive intestinal polypeptide (VIP) by intraduodenal stimuli.
    Schaffalitzky de Muckadell OB; Fahrenkrug J; Holst JJ; Lauritsen KB
    Scand J Gastroenterol; 1977; 12(7):793-9. PubMed ID: 594650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.